ARS Pharmaceuticals reports Q1 EPS (35c), consensus (36c)

Reports Q1 revenue $7.973M, consensus $7.48M. “We’ve built strong momentum for neffy’s U.S. launch and are well positioned heading into the peak epinephrine prescribing season this summer,” said Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma. “Children represent almost half of the prescriptions for epinephrine, underscoring the critical need for a needle-free, easy-to-use, easy-to-carry epinephrine option. We’ve had solid wins in market access, and the accelerated sales force expansion with our ALK partnership expands our reach to key pediatricians ahead of summer travel and the back-to-school season. Coupled with compelling clinical data and enhanced real-world adoption, we believe neffy is positioned to become the standard of care for those at risk of severe allergic reactions and a leading treatment option in the category.”